A US rare-disease biotech that signed an EU licensing agreement in 2023 or 2024 has, somewhere in that agreement, a milestone clause keyed to "grant of orphan market exclusivity in the European Union" or an earnout schedule keyed to "extension of orphan designation for an additional indication." Those clauses were drafted against Regulation (EC) No 141/2000,1Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products, the predecessor framework that Art. 179(1) of the Pharma Package Regulation is set to repeal; ten-year market exclusivity under Art. 8(1). the framework that governed orphan exclusivity in the Union for a quarter-century and is now ending. The final compromise text of the Pharma Package, published on 6 March 2026, restructures orphan exclusivity in ways that do not map cleanly onto the contractual primitives those agreements use. The deal language still functions; the right it points at has changed shape. For the US biotech treasurer running an EU-revenue net-present-value model, for the outside counsel drafting an outbound license, and for the buyer running diligence on a rare-disease asset, how long EU exclusivity lasts matters less than what kind of right it still is.
1. From Indication-Based to Product-Based: The Structural Pivot
Under Regulation (EC) No 141/2000 (the "Orphan Regulation"), the unit of orphan exclusivity was the designated indication. Art. 8 of the Orphan Regulation conferred ten years of market exclusivity for the same therapeutic indication in respect of a similar medicinal product. If a sponsor obtained a second orphan designation for the same active substance in a different rare-disease indication and obtained a marketing authorization on it, that second indication generated its own ten-year clock running from its own grant date. Indication-stacking, the strategy of pursuing sequential orphan designations on a single substance so that each indication carries its own exclusivity period, was built into the Orphan Regulation.
The Pharma Package recodifies the orphan regime in Chapter VI of the proposed Regulation.2Final compromise text for a Regulation laying down Union procedures for the authorisation and supervision of medicinal products for human use, Council doc ST-6366/26 (24 February 2026, confirmed by Coreper on 6 March 2026), Chapter VI (Art. 63 to 73). Art. 71 of the Regulation continues to describe a right denominated in years and tied to a "same therapeutic indication" condition for similar medicinal products. The continuity is superficial. Art. 71(3) of the Regulation provides that where the same marketing authorization holder holds more than one orphan marketing authorization for the same active substance, those authorizations "shall not benefit from separate market exclusivity periods" and "the duration of the market exclusivity shall start from the date when the first orphan marketing authorisation was granted in the Union." The unit of exclusivity has migrated from the designation to the active substance.
The Pharma Package shortens the standard orphan baseline from ten to nine years and the well-established-use tier to four, while introducing an eleven-year breakthrough tier; the more consequential change is that orphan exclusivity now attaches to the active substance rather than the indication, with prolongation capped at the margin.
That shift has three immediate consequences for how value is calculated. First, the clock no longer runs separately on each rare-disease indication. The strategic option of using a second orphan designation to reset the protection horizon is closed; under Art. 71(3) of the Regulation the second authorization inherits the first authorization's clock. Second, prolongation for new orphan indications, addressed in Art. 72(2) of the Regulation, is bounded both in number (granted at most twice) and in magnitude (twelve months per grant). Third, the standard regulatory data and market protection framework in the companion Directive3Final compromise text for a Directive on the Union code relating to medicinal products for human use, Council doc ST-6367/26 (24 February 2026, confirmed by Coreper on 6 March 2026), Art. 80 to 85. sits beneath the orphan regime as a floor, and the two regimes are designed not to stack, an interaction taken up in section 4 below.
The numerical movement is real but secondary. What dominates the restructure is the categorical one. The orphan exclusivity contemplated by the Pharma Package is a substance-anchored right with capped prolongation. The orphan exclusivity contemplated by the Orphan Regulation was a series of indication-anchored rights with no internal cap. A deal clause keyed to one of these objects does not automatically migrate to the other. This shift is deliberate: the Union's aim was to curb the indication-stacking that let one substance accumulate open-ended orphan protection, and Recital 104 of the Regulation recasts the new-indication reward as a bounded one-year-per-indication incentive rather than a fresh clock. Where the open terms examined below are ambiguous, that purpose points toward the narrower, cap-respecting reading.
2. 9 Years, 11 Years, and the "Breakthrough" Qualification
Art. 71(2) of the Regulation sets three baseline durations. Standard orphan products receive nine years of market exclusivity (Art. 71(2)(a) of the Regulation). "Breakthrough" orphan medicinal products as referred to in Art. 70 of the Regulation receive eleven years (Art. 71(2)(b) of the Regulation). Products authorized under the well-established-use pathway in Art. 13 of the Directive receive four years (Art. 71(2)(c) of the Regulation). The Orphan Regulation's ten-year baseline is gone in both directions: the new standard is one year shorter, the new top tier is one year longer, and the top tier is gated by a substantive qualification test that did not exist in the Orphan Regulation.
That test, set out in Art. 70(1) of the Regulation, has two limbs that operate cumulatively. The first limb requires that "there is no medicinal product authorised in the Union for the orphan condition"; the compromise text strikes the alternative, carried over from the Commission's proposal, for a product that "in addition to having a significant benefit, will bring exceptional therapeutic advancement" despite authorized competitors. The second limb requires that "the use of the orphan medicinal product results in a clinically relevant reduction in disease morbidity or mortality for the relevant patient population." Art. 70(2) of the Regulation excludes products authorized through the well-established-use pathway from breakthrough status, and the compromise text strikes Art. 70(3) of the Regulation, under which the Agency would have adopted scientific guidelines for the test.
How the breakthrough determination is made matters for valuation in ways that the language of a milestone clause may not capture. The first limb is a market fact rather than a clinical standard: it fails if any medicinal product is authorized in the Union for the orphan condition when the determination is made, so a competitor authorized first can move a program that met the test at phase-3 design down to the nine-year tier. The second limb's "clinically relevant reduction in disease morbidity or mortality" has no numerical floor stated on the face of the Regulation, and with Art. 70(3) of the Regulation struck, the text no longer points to EMA guidance as the place where that floor will be set.
This is the procedural asymmetry that an outbound license drafted today must accommodate. Whether an asset clears the eleven-year tier or the nine-year tier turns on a categorical determination made at marketing-authorization time by the Committee for Medicinal Products for Human Use (the Pharma Package abolishes the separate Committee for Orphan Medicinal Products and folds orphan assessment into the CHMP), applying a second limb that the Regulation states only in general terms, against a clinical-evidence package designed several years earlier. The two-year delta between the tiers (roughly twenty-two percent of the standard exclusivity period) is not a trivial commercial difference, and the determination is binary. The clinical and regulatory teams that draft the marketing-authorization dossier will be the ones who, in effect, allocate that delta. The deal team will see the outcome only after the fact.
The transitional rule in Art. 180(7a) of the Regulation, taken up in section 6 below, keeps the Orphan Regulation's ten-year period only for an initial marketing authorization applied for before the date of application; it does not shield follow-on indications, even those applied for before that date.
One technical interaction warrants flagging for breakthrough programs specifically. Art. 81(2) of the Directive, the standard regulatory protection framework that interlinks with the orphan regime, contains a carve-out for conditional marketing authorizations: the unmet-medical-need prolongation of Art. 81(2)(a) of the Directive applies only if the conditional authorization converts to a full marketing authorization within four years of the conditional grant, in accordance with Art. 19(7) of the Regulation. Because breakthrough orphan products are more likely than standard orphan products to take the conditional approval pathway, the four-year window governs whether that twelve-month prolongation of regulatory market protection can be captured. It no longer reaches the orphan exclusivity itself: the compromise text strikes Art. 72(1) of the Regulation, the orphan-side prolongation that cross-referred to Art. 81(2)(a) and Art. 82(1) of the Directive, so a breakthrough sponsor that does not convert in time loses the Directive-side year while its eleven-year exclusivity under Art. 71(2)(b) of the Regulation, and the substance-level clock under Art. 71(3) of the Regulation, are unaffected.
3. The Two-Indication Cap and Why Indication-Stacking Collapses
In the compromise text, Art. 72 of the Regulation keeps a single prolongation route on top of the baselines in Art. 71(2)(a) and (b) of the Regulation. Art. 72(1) of the Regulation, the twelve-month "Union market launch" prolongation of the Commission's proposal, is struck, as is Recital 103 of the Regulation, which explained it. Art. 72(2) of the Regulation provides a twelve-month prolongation for a new therapeutic indication for a different orphan condition, granted at most twice. A breakthrough orphan that uses both grants under Art. 72(2) of the Regulation reaches a theoretical maximum envelope of thirteen years (eleven plus two), which is the new ceiling for an EU orphan asset.
Art. 72(2) of the Regulation is the provision that collapses indication-stacking. It prolongs the periods of market exclusivity referred to in Art. 71(2)(a) and (b) of the Regulation by twelve months "if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition." The second subparagraph then sets the cap directly: "Such a prolongation may be granted twice, if the new therapeutic indications are each time for different orphan conditions." Recital 104 of the Regulation states the policy intention in the same terms, noting that "an additional period of one year of market exclusivity is provided for a new therapeutic indication (with a maximum of two indications)."
Two operational uncertainties sit beneath the framework of Art. 72(2) of the Regulation. The first is what counts as a "different orphan condition." The Regulation does not define the term on its face; the criteria in Art. 63 of the Regulation (prevalence and unmet medical need) govern what qualifies as an "orphan condition" for designation purposes, but whether two new indications attached to the same active substance constitute "different orphan conditions" or variants of one is a question the Regulation leaves open. Commission Regulation (EC) No 847/2000,4Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts ‘similar medicinal product’ and ‘clinical superiority’ [2000] OJ L103/5; preserved by transitional Art. 180(12) of the Regulation. preserved by transitional Art. 180(12) of the new Regulation, defines the cognate concepts of "similar medicinal product" (controlling what Art. 71(1) of the Regulation blocks) and "clinical superiority" (controlling one of the derogations in Art. 71(4) of the Regulation), but it does not define "different orphan condition." The clinical-superiority derogation in particular is not theoretical: under Art. 71(4)(c) of the Regulation, a competitor can obtain a marketing authorization for a similar medicinal product within the original product's exclusivity window if it demonstrates that the competing product is "safer, more effective or otherwise clinically superior." For inbound diligence on a rare-disease asset, that derogation means the substance-anchored exclusivity is not absolute. Sponsors planning a second or third orphan designation on the same active substance face a definitional gap that no provision of the Regulation closes.
The second uncertainty is a timing constraint that the substance-level clock introduces. Because the clock runs from the first orphan marketing authorization under Art. 71(3) of the Regulation, and because Art. 72(2) of the Regulation requires the new indication to be granted at least two years before exclusivity expiry, a follow-on indication on a standard nine-year orphan must be approved by year seven of the substance clock; for a breakthrough eleven-year orphan, by year nine. Programs that under the Orphan Regulation could deliver value into the lead indication's commercial window at any point during its ten-year period now have a hard deadline driven by the substance, not the indication. For platform companies built around sequential orphan designations on a single active substance, the deadline is the variable that most directly constrains development sequencing.
Under the Orphan Regulation, indication-stacking was not a prolongation mechanism. Each new orphan designation could lead to its own marketing authorization, and each authorization generated its own ten-year clock for its own indication, running independently. A sponsor that secured three sequential orphan designations on the same substance across three rare-disease conditions could end up with three overlapping exclusivity periods, the last of which expired well after the first. The total period of exclusivity was not capped, and the unit of value (a fresh ten-year period per indication) was, for valuation purposes, a multiplier rather than a one-time prolongation.
Under Art. 71(3) of the Regulation the multiplier is gone, and under Art. 72(2) of the Regulation the surviving prolongation mechanism is limited in four ways. It is limited in number (granted at most twice). It is limited in magnitude (twelve months per grant, not a fresh exclusivity period). It is limited in qualifying conditions (a "different orphan condition" each time, with the underlying condition having to satisfy the prevalence and unmet-need criteria in Art. 63 of the Regulation afresh). And it is limited in timing (the prolongation must be obtained at least two years before the end of the exclusivity period to which it attaches, which constrains how late in the lifecycle a second-indication program can deliver value into the original product's commercial window).
A Worked Example
Take a substance whose first orphan marketing authorization is granted in 2030 on the standard nine-year tier: under Art. 71(3) of the Regulation that single clock runs to 2039 for every orphan indication the holder authorizes on the substance, whenever each is authorized. Two further indications, each for a different orphan condition and each approved in time to meet the two-years-before-expiry condition in Art. 72(2) of the Regulation, add twelve months apiece and take the clock to 2041; that is the ceiling, because the prolongation may be granted at most twice. Any further orphan indication on the substance adds nothing. Under the Orphan Regulation those same indications, designated and authorized across 2030, 2033, 2036 and 2039, would each have run an independent ten-year clock, the fourth expiring in 2049, with no aggregate cap. The Pharma Package thus compresses several independent decade-long clocks into one substance clock plus, at most, two new-indication bonus years; the one-year Union-launch prolongation that the Commission proposed in Art. 72(1) of the Regulation is struck from the compromise text.
The change also affects how follow-on programs are valued. Under the Orphan Regulation, a follow-on indication could be planned to bring its own period of exclusivity at a future date, and the pre-clinical and clinical investment necessary to develop it was, in part, justified by the value of that later period. Under the Pharma Package the same investment can deliver at most twelve months of additional protection on the original product's clock, and only if it lands at least two years before the clock runs out, and only if it is one of two such investments the product can capitalize on. Follow-on programs three, four, and five, each a viable strategy under the Orphan Regulation for a substance with broad therapeutic potential across rare diseases, deliver no incremental exclusivity at all. They may still be commercially worthwhile, but they have to justify themselves on indication-level revenue alone, no longer on an exclusivity period of their own.
For US biotechs whose business model relied on indication-stacking, including platform companies whose investment thesis was built on serial orphan designation, the cap forecloses the strategy in the Union. The US Orphan Drug Act (ODA), addressed in section 5 below, has no equivalent cap, and the strategic analysis that follows rests on the transatlantic asymmetry that results.
4. PIP Extension Removed; the SPC Substitute Is Patent-Contingent
The Pharma Package repeals Regulation (EC) No 1901/20065Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use, which Art. 179(1) of the Regulation is set to repeal; Art. 37 conferred the two-year paediatric extension on orphan market exclusivity. in its entirety (Art. 179 of the Regulation). With that repeal goes Art. 37 of Regulation (EC) No 1901/2006, the provision that permitted orphan medicinal products completing an agreed pediatric investigation plan (PIP) to extend their orphan market exclusivity by two years, taking the Orphan Regulation's ten-year period to twelve. The new pediatric framework consolidated in Chapter VII of the Regulation does not preserve that reward. Art. 93 of the new Regulation, which addresses rewards under the pediatric-use marketing-authorization procedure, refers only to the regulatory data and market protection periods of Art. 80 and Art. 81 of the Directive. It does not refer to any orphan-specific extension and does not replicate Art. 37 of Regulation (EC) No 1901/2006.
The six-month supplementary protection certificate (SPC) extension under Regulation (EC) No 469/2009,6Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products, the instrument under which the six-month paediatric SPC extension operates. the pediatric reward that Regulation (EC) No 1901/2006 reserved for non-orphan products, now sits in the Package itself: Art. 86(1) of the Directive entitles the holder of the patent or certificate to the extension where the marketing-authorization application includes the results of all studies conducted under an agreed pediatric investigation plan, and Art. 86 of the Directive contains no counterpart to the orphan exclusion in Art. 36(4) of Regulation (EC) No 1901/2006. The Package text flags a future replacement for Regulation (EC) No 469/2009 (the placeholder "OP please replace reference by new instrument when adopted" recurs across the Package's definitions and cross-references), which signals the legislative intention but does not alter the substantive trigger for the SPC extension. The practical question, then, is what an orphan sponsor that successfully completes a pediatric investigation plan now receives in return.
The answer depends on the patent estate. Where the orphan substance is covered by a basic patent and a granted supplementary protection certificate, the sponsor may capture a six-month SPC extension on the certificate's term. Where the orphan substance is not covered by a basic patent (because the substance is naturally-occurring, structurally unprotectable, or because patent protection has lapsed before SPC application), or where no SPC has been granted, the six-month extension has no underlying right to attach to. The orphan-specific reward that previously sat on the regulatory side of the wall is no longer available. The pediatric program that under the Orphan Regulation plus Regulation (EC) No 1901/2006 mechanically converted into two years of additional market exclusivity now converts into zero, six months, or some intermediate value, depending on patent inventory.
That shift moves a category of orphan-development risk from the regulatory column to the patent column. Under the Orphan Regulation and Regulation (EC) No 1901/2006, the value of the pediatric program was a regulatory entitlement that did not depend on the strength of the patent estate. Under the Pharma Package, the value of completing the pediatric program depends on whether the substance has a valid and timely SPC. For substances whose intellectual-property profile is built on regulatory exclusivity rather than composition-of-matter patents (a common posture for repurposed compounds, naturally-derived substances, biologics whose key claims are functional rather than structural, and substances licensed in from academic inventors with imperfect patent prosecution histories), the loss of Art. 37 of Regulation (EC) No 1901/2006 is not offset by the SPC pathway.
The companion Directive's own protection periods also bear on orphan products. Art. 80 of the Directive establishes the standard regulatory data protection period; Art. 81 of the Directive sets the prolongation framework. Art. 72(3) of the Regulation excludes orphan products that have already obtained a new-indication prolongation under Art. 72(2) of the Regulation from the Directive's new-indication extension, which the final compromise text places in Art. 81(2a) of the Directive. Orphan products that capture the orphan-side prolongation forfeit the Directive-side prolongation. The two are alternatives, not complements, by design.
5. Comparative: US ODA Indication-Based Exclusivity and the Widening Transatlantic Asymmetry
The comparative analysis that follows treats the EU-US axis. The Swiss orphan-drug regime under the Heilmittelgesetz (HMG) is a separate question: it is aligned with neither the Orphan Regulation nor the new Pharma Package framework, and this analysis leaves it aside. One bridge is worth noting, however: a Swiss-domiciled sponsor, or one that files Swissmedic-first, gains nothing in the Union from that sequencing, because the substance-level clock and the transitional cut-off attach on the EU marketing-authorization application itself; a Basel-based group structuring a transatlantic launch faces the same arithmetic under Art. 71(3) of the Regulation as a US one.
The US Orphan Drug Act721 U.S.C. § 360cc; Orphan Drug Act, Pub L No 97-414, 96 Stat 2049 (1983), as amended; seven-year exclusivity for designated orphan drugs. makes a different choice. Section 527 of the Federal Food, Drug, and Cosmetic Act (codified at 21 U.S.C. § 360cc) provided, until its amendment on 3 February 2026, that, on approval of an application for an orphan-designated drug, the Food and Drug Administration could not approve another application for "the same drug for the same disease or condition" for seven years. The exclusivity period is shorter than the EU equivalent, but it has historically operated as an indication-based right, anchored by FDA's regulations (21 CFR Part 316) which tie exclusivity scope to the approved use or indication within the orphan-designated disease or condition.
Three events between 2021 and 2026 have settled that picture along the indication-based line. In Catalyst Pharms., Inc. v. Becerra,8Catalyst Pharms., Inc. v. Becerra, 14 F.4th 1299 (11th Cir. 2021); the decision read 21 U.S.C. § 360cc to extend orphan exclusivity to the full designated disease or condition rather than only the approved indication. the United States Court of Appeals for the Eleventh Circuit held that the statutory phrase "same drug for the same disease or condition" extends the exclusivity to the full designated disease or condition rather than only the approved indication, reading the statute literally and declining to defer to FDA's narrower regulation. The FDA responded with a Federal Register notice on 24 January 2023 stating that, while it had complied with the court's order in respect of the affected product, the agency would "continue to apply its regulations tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved."9FDA, "Clarification of Orphan-Drug Exclusivity Following Catalyst Pharms., Inc. v. Becerra; Notification" (2023) 88 Fed Reg 4086 (24 January 2023). Congress then resolved the statutory question. Section 6605 of the Consolidated Appropriations Act, 2026,10Consolidated Appropriations Act, 2026, Pub. L. 119-75, § 6605 (3 February 2026), incorporating the Mikaela Naylon Give Kids a Chance Act, amending 21 U.S.C. § 360cc to substitute "same approved use or indication within such rare disease or condition" for "same disease or condition," applicable retroactively to all orphan-designated drugs. enacted on 3 February 2026, amended 21 U.S.C. § 360cc to substitute "same approved use or indication within such rare disease or condition" for the phrase the Eleventh Circuit had construed in Catalyst. The amendment codifies FDA's pre-Catalyst indication-based interpretation, applies retroactively to all orphan-designated drugs, and brings the statute into line with 21 CFR Part 316. The US framework is therefore now firmly indication-anchored, both at the regulatory level and at the level of statute, with the same drug capable of supporting separate seven-year exclusivity periods for separate approved indications within the same designated disease or condition. The narrowing runs in both directions: it lets the original sponsor accrue indication-level periods, and it equally lets competitors enter for uses within the designated condition that the originator has not itself secured.
The US framework, now affirmed by both statute and regulation, treats orphan exclusivity as a right that runs separately on each approved indication within a designated disease or condition; a second indication can support a second exclusivity period. The EU framework, after the Pharma Package, treats orphan exclusivity as a right that runs on the active substance and is capped at two twelve-month prolongations for follow-on indications. The same rare-disease asset, developed across the same set of indications, generates a categorically different exclusivity profile in the two jurisdictions. The duration delta is not the asymmetry that matters. The asymmetry that matters is that the two regimes now protect different objects.
For a US biotech that has built its commercial logic on indication-stacking, the Union side of a global launch model has been re-engineered. A pipeline strategy that under the ODA and the Orphan Regulation could yield three indication-level orphan periods of seven and ten years respectively, running on parallel clocks, now yields three indication-level seven-year periods on the US side and at most a single nine-year (or eleven-year) substance-level period with two twelve-month prolongations on the EU side. The EU revenue envelope shrinks not because the duration is shorter, but because the prolongation mechanism is capped and the indications no longer reset the clock.
The same shift cuts in the other direction for products that secure the eleven-year breakthrough tier on a single indication. A US biotech with one rare-disease asset and one indication, where the asset can clear the breakthrough test in Art. 70 of the Regulation, ends up with eleven years in the EU and seven years in the US, widening the EU's lead from three years to four. The substance-level clock favors single-indication breakthrough products and works against multi-indication platforms; the Orphan Regulation, together with Regulation (EC) No 1901/2006, favored the second profile. The Pharma Package has not raised or lowered the absolute level of orphan protection so much as it has redistributed protection between two profiles of rare-disease developer.
6. Strategic Considerations: M&A Earnouts, Licensing Milestones, Pipeline Valuation
The first question this analysis would put to a US biotech treasurer is whether the existing licensing and milestone language in its outbound EU agreements still describes the right the counterparty is now buying. A milestone keyed to "grant of orphan market exclusivity in the European Union for a second indication" was, under the Orphan Regulation, a milestone keyed to a fresh ten-year clock running from a fresh authorization date; under the Pharma Package, the same words now point at a twelve-month prolongation of a clock that was set when the first indication was authorized, with the prolongation grantable at most twice. Is the contractual definition tracking the document, the duration, or the underlying economic value? In most outbound licenses drafted before the final compromise text was visible, the definition tracks the document. The contracting parties did not intend, but did not contractually exclude, the possibility that what they were defining would devalue without re-papering.
A second question concerns transitional treatment for assets that straddle the dates of application. Art. 180 of the Regulation grandfathers orphan designations granted before the date of application, but Art. 180(7a) of the Regulation makes clear that the Orphan Regulation's ten-year exclusivity period applies only to the initial marketing authorization; any subsequent application for an orphan medicinal product containing the same active substance is subject to Art. 71(3) and Art. 72 of the new Regulation. Read literally, the second subparagraph extends this restriction to applications submitted before the date of application of the new Regulation: even an application filed pre-cliff falls under Art. 71(3) and Art. 72 of the Regulation unless it is the "initial" application. For a substance where two or more orphan marketing-authorization applications are simultaneously pending, the Regulation does not say which one counts as initial. Sponsors with parallel orphan applications close to the transitional date should plan around that ambiguity rather than assume it resolves in their favor. For a pipeline that contains a phase-3 lead indication approaching its first marketing-authorization submission and one or more phase-2 follow-on indications behind it, the question is which side of the transitional cliff the lead indication's initial application will land on. The economic difference between the two sides is material, and because the choice of which indication to file first now has multi-year exclusivity consequences for the second, it is no longer a decision for regulatory affairs alone.
A third question concerns diligence on inbound-licensed assets. For a US buyer evaluating an EU-developed rare-disease asset, the historical diligence checklist asked about orphan designation status, indication coverage, and remaining exclusivity term. Under the Pharma Package, those questions need to be supplemented by a substance-level inquiry: how many orphan marketing authorizations the holder has obtained on the same active substance, when the first such authorization was granted, whether any prolongations under Art. 72(2) of the Regulation have been used or remain available, and whether the asset has been validated as a "breakthrough orphan medicinal product" under Art. 70 of the Regulation. The valuation impact of each of those facts is now higher than under the Orphan Regulation, because each constrains the substance-level clock that controls the entire portfolio attached to that substance.
A fourth question concerns the treatment of pediatric programs in valuation models. The two-year extension under Art. 37 of Regulation (EC) No 1901/2006 was, for orphan products, a regulatory entitlement; for portfolio valuation purposes, it was often modeled as a near-certainty once the pediatric program was committed to. The substitute SPC pathway is contingent on the substance's patent estate, on SPC grant, and on SPC term. For substances with a strong composition-of-matter patent position and a granted SPC, modeling the six-month SPC extension is straightforward. For substances whose intellectual-property position is built primarily on regulatory exclusivity, the valuation team may now be modeling a zero. This is a diligence and modeling delta that an M&A deal team needs to surface explicitly, not absorb into the same line-item that previously carried the twenty-four-month extension.
A fifth question concerns earnouts. An earnout event keyed to "extension of orphan market exclusivity in the European Union" was, under the Orphan Regulation and Regulation (EC) No 1901/2006, a fairly clear event that completing a pediatric program could trigger. Under the Pharma Package, the corresponding events are the new-indication prolongation under Art. 72(2) of the Regulation and possibly the breakthrough qualification under Art. 70 of the Regulation; the Union-launch prolongation that the Commission proposed in Art. 72(1) of the Regulation is struck from the compromise text. The two events differ: each requires different evidence and different timing relative to the original clock, and the prolongation under Art. 72(2) of the Regulation is capped at two grants. An earnout schedule that uses the singular phrase to capture both is at best ambiguous and at worst silently undefined. The drafting question is whether to re-paper the earnout to enumerate the Pharma Package events explicitly, or to fix the economic substance of what triggers payment irrespective of regulatory taxonomy.
The overall observation is that the Pharma Package has not made EU orphan exclusivity better or worse in absolute terms. It has made EU orphan exclusivity a different object than the one contractually contemplated by a generation of outbound EU licenses. What follows is the work of mapping the old contract terms onto the new regulatory rights and deciding, deal by deal, whether the mapping holds.